Dallas- OTCPicks.com’s Daily OTC Stocks Newsletter presents a range of the hottest small cap, micro cap and penny stocks trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and micro cap traders to meet up and discuss their top stock picks. Visit http://www.otcpicks.com/hotpicks.htm today to sign up for our Free Daily Email Newsletter and News Alerts.
Sign up for our Free Red Hot Stock Picks List at http://www.otcpicks.com/hotpicks.htm Join us on Twitter at www.twitter.com/otcpicks Join us on Facebook at www.facebook.com/otcpicks
OROFINO GOLD CORPORATION (OTC: ORFG) "Up 5.36% in morning trading" Company Profile: http://www.otcpicks.com/orofino-gold/orofino-gold.htm Orofino Gold is a precious metals acquisition, exploration, and development company. The Company acquires and explores strategically-located precious metals properties in the historically rich gold bearing jurisdictions of Colombia and Mexico. To this end OROFINO has signed an option agreement to acquire several properties in Colombia. The Company is listed on the Pink Sheets under the symbol ORFG.
TRANS-PACIFIC AEROSPACE CO. INCORPORATED (OTCBB: TPAC) Trans-Pacific Aerospace Company plans to use its proprietary aerospace bearing technologies to manufacture and sell component parts for both new commercial aircraft and spares for the existing commercial fleet, initially through a joint venture in China. The component parts are referred to as self-lubricating spherical bearings, and they help with several flight critical tasks including aircraft flight controls and landing gears.
MED GEN INCORPORATED (OTCBB: MDIN) "Up 100.00% in morning trading" Med Gen Inc., in business since 1996, manufactures and markets specialty products using its proprietary delivery system, Spray’s the Way (“STW”). It is best known for producing the world’s first patented liquid spray snoring relief formula, Snorenz®. Since its existence, Med Gen has continued to develop its STW technology, introducing Good Nights Sleep®, the UnDiet® system and GOOD NIGHTS SLEEP® Sleep Strips into its family of brands. FabULust™, the company’s newest product, a female sexual stimulant, has been launched in test markets throughout the country. While STW technology is mainly used, the company also produces other products that deal with common health issues using other delivery systems. The company markets its products to distributors, direct sales via the company web site and direct to consumer television, radio and print advertising. The company also distributes its brands internationally under various private labels or existing names. The Company also offers specialty financial and investment services through its Financial Services division, to small emerging public companies.
ARRAY BIOPHARMA INCORPORATED (NASDAQ: ARRY) "Up 32.12% in morning trading" Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.
GENTA INCORPORATED (OTCBB: GETA) "Up 22.36% in morning trading" Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States.
BIONEUTRAL GROUP INCORPORATED (OTCBB: BONU) "Up 17.65% in morning trading" Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene and Ogiene, which are eco-friendly and include natural and common ingredients found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications.
